Cameron Turtle - Feb 15, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Feb 15, 2024
Transactions value $
$3,928
Form type
4
Date filed
2/20/2024, 09:21 PM
Previous filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Award $3.93K +400 +0.05% $9.82 747K Feb 15, 2024 Direct F1, F2

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.